Medtronic/RTI
This article was originally published in The Gray Sheet
Executive Summary
Revised human allograft exclusive worldwide distribution agreement includes an option for Medtronic Sofamor Danek to purchase up to $10 mil. of Regeneration Technologies stock. The pact, which relates to RTI's specialty tissue allografts and bone paste used in spinal surgery, also calls for an increase in the licensing and transfer fees paid by Medtronic from 30% to "40-50%," RTI says. The restructured agreement reflects "the value of RTI's proprietary technology," including the BioCleanse tissue sterilization process, according to a June 19 RTI release. A next generation version of the BioCleanse process, introduced June 12, sterilizes tissue from single donors in separate chambers, eliminating the need to batch tissue from multiple donors...
You may also be interested in...
Cohesion Sale Drives Shares In September; O-T-C Index Composite Declines
Cohesion Technologies shares spiked 64% on Sept. 30, the day the firm announced its acquisition by Angiotech Pharmaceuticals. The issue closed September at $3.86, an 81% gain for the month overall
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.